Last $1.99 USD
Change Today -0.07 / -3.40%
Volume 1.8M
GALE On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 10/1/14 All times are local (Market data is delayed by at least 15 minutes).

galena biopharma inc (GALE) Snapshot

Open
$2.04
Previous Close
$2.06
Day High
$2.05
Day Low
$1.92
52 Week High
01/14/14 - $7.77
52 Week Low
04/15/14 - $1.66
Market Cap
235.2M
Average Volume 10 Days
1.6M
EPS TTM
$-0.78
Shares Outstanding
118.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GALENA BIOPHARMA INC (GALE)

Related News

No related news articles were found.

galena biopharma inc (GALE) Related Businessweek News

No Related Businessweek News Found

galena biopharma inc (GALE) Details

Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing and commercializing oncology treatments that address major unmet medical needs to advance cancer care. Its commercial product includes Abstral, a sublingual tablet, which is used as treatment option for breakthrough cancer pain in patients. The company’s lead product candidate comprise NeuVax (nelipepimut-S or E75), which has completed Phase III clinical trials for preventing the recurrence of breast cancer; and Phase IIb clinical trials in combination with Herceptin for the treatment of breast cancer. It also develops GALE-301 or Folate Binding Protein (FBP), a therapeutic target that has completed Phase II clinical trials for the treatment of ovarian and endometrial cancers; and GALE-401 (Anagrelide CR), which has completed Phase I studies for the treatment of essential thrombocythemia. Galena Biopharma, Inc. has strategic partnership with Dr. Reddy's Laboratories Ltd. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Galena Biopharma, Inc. in September 2011. Galena Biopharma, Inc. was founded in 2003 and is based in Lake Portland, Oregon.

60 Employees
Last Reported Date: 03/17/14
Founded in 2003

galena biopharma inc (GALE) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: $490.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $236.0K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $127.3K
Compensation as of Fiscal Year 2013.

galena biopharma inc (GALE) Key Developments

Galena Biopharma, Inc. - Special Call

To discuss the company's responses to the recommendations and provide an update on Abstral(fentanyl) sublingual tablets and the status of NeuVax (nelipepimut-S) enrollment

Galena Biopharma, Inc. Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014

Galena Biopharma, Inc. Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 . Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States.

Galena Biopharma Provides Update on Phase 2 Clinical Trial

Galena Biopharma, Inc. announced the first patient has been dosed in the GALE-401, or Anagrelide Controlled Release (CR), Phase 2 Clinical Trial. The Phase 2 study will treat patients with elevated platelet counts in myeloproliferative neoplasms (MPNs) including essential thrombocythemia (ET). Based on discussions with the U.S. Food and Drug Administration (FDA) and pending a successful development program, Galena would pursue approval via the 505(b)(2) regulatory pathway. The Phase 2 trial is an open-label, single-arm, multicenter study of GALE-401 in 20 patients with MPN-related thrombocytosis. The goals of the study are to confirm the platelet-lowering activity of GALE-401 in patients with MPNs, to assess safety and tolerability, and to measure blood levels of the drug. The primary efficacy endpoint will be the proportion of subjects who achieve a complete or partial platelet response for at least four weeks during the first six months of treatment. MPNs encompass a family of diseases including essential thrombocythemia, polycythemia vera, primary myelofibrosis, and chronic myelogenous leukemia. The active ingredient immediate release version of anagrelide has been shown to reduce excessive platelet counts and has been approved by the FDA for treating high platelet counts in patients with MPNs. Anagrelide CR is Galena's new formulation of anagrelide that releases the active ingredient more slowly over time than currently marketed versions of this drug, and is therefore absorbed more slowly into the bloodstream.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GALE:US $1.99 USD -0.07

GALE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Benitec Biopharma Ltd A$1.00 AUD -0.005
Prosensa Holding NV $8.49 USD +0.06
Regulus Therapeutics Inc $6.66 USD -0.17
Silence Therapeutics PLC 203.50 GBp +3.50
Tekmira Pharmaceuticals Corp C$27.85 CAD +4.11
View Industry Companies
 

Industry Analysis

GALE

Industry Average

Valuation GALE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 34.8x
Price/Book 8.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 27.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GALENA BIOPHARMA INC, please visit www.galenabiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.